Impact Biomedical (IBO) Non-Current Assets (2022 - 2026)

Impact Biomedical (IBO) has reported Non-Current Assets for 5 consecutive years, with $16.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets fell 6.56% year-over-year to $16.4 million; the trailing twelve-month figure through Jun 2026 stood at $67.4 million (down 30.36% YoY), and the FY2025 full-year result was $17.0 million, down 4.75% from the prior year.
• Non-Current Assets eased to $16.4 million in Q2 2026 per IBO's latest filing, from $16.7 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $46.4 million in Q4 2022 and bottomed at $16.4 million in Q2 2026.
• Historically, Non-Current Assets has averaged $30.9 million across 5 years, with a median of $30.7 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets decreased 2.38% in 2024, then tumbled 60.27% in 2025.
• Over 5 years, Non-Current Assets stood at $46.4 million in 2022, then decreased by 4.47% to $44.3 million in 2023, then slumped by 59.73% to $17.8 million in 2024, then decreased by 4.75% to $17.0 million in 2025, then declined by 3.35% to $16.4 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $16.4 million, $16.7 million, and $17.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.